ADA26: Early data for teplizumab demonstrates promise for slowing T1D progression

Real-world data presented at ADA 2026 showcased the impact of Sanofi's teplizumab in slowing type 1 diabetes (T1D) progression. Real-world data presented at ADA 2026 showcased the impact of Sanofi's teplizumab in slowing type 1 diabetes (T1D) progression. Teplizumab slows the progression of T1D by preventing the destruction of insulin-producing cells in the pancreas. Credit: Explode/Shutterstock.com. During the 2026 American Diabetes Association (ECO) Scientific Sessions in New Orleans, a real-world cohort of type 1 diabetic (T1D) patients was analyzed for outcomes after treatment with teplizumab, including insulin usage and overall disease progression. However, usage of teplizumab has been limited to…

Source: Clinical Trials Arena